Vistagen Therapeutics investors file class action securities lawsuit.

miércoles, 4 de marzo de 2026, 9:05 am ET1 min de lectura
VTGN--

Vistagen Therapeutics investors who lost money between April 1, 2024 and December 16, 2025, may be eligible for a class action lawsuit. The lawsuit alleges that the company engaged in securities fraud by providing false or misleading statements about its Phase 3 PALISADE-3 trial study of fasedienol. Investors can contact Levi & Korsinsky, LLP for more information and to be contacted by a team member.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios